Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13293899 | 0.98 | TSHR (0.35) | TSHRCYP2C19POLBFPR2ATM | |
| SCHEMBL16553553 | 0.75 | TSHR (0.38) | TSHRCYP2C19POLBATM | |
| SCHEMBL15026088 | 0.75 | CYP2C19 (0.46) | TSHRCYP2C19POLBFPR2ATM | |
| SCHEMBL1362594 | 0.74 | TSHR (0.37) | TSHRCYP2C19POLBATM | |
| SCHEMBL3126654 | 0.65 | POLB (0.52) | TSHRCYP2C19POLB | |
| Hydrochloric Acid SCHEMBL2209606 | 0.63 | — | — | |
| SCHEMBL21150662 | 0.61 | MEN1 (0.35) | TSHRCYP2C19 | |
| SCHEMBL21150663 | 0.61 | CHRNB4 (0.35) | — | |
| SCHEMBL6239127 | 0.61 | TSHR (0.36) | TSHRCYP2C19POLBATM | |
| SCHEMBL1362082 | 0.61 | TSHR (0.36) | TSHRCYP2C19POLBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2341777-B1 | ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS | NOVABAY PHARMACEUTICALS INC (US) | 2015-01-21 | — | — | EP | disclosed |
| US-8722715-B2 | Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions | NovaBay Pharmaceuticals (US) | 2014-05-13 | — | — | US | disclosed |
| US-20100137349-A1 | ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS | NOVABAY PHARMACEUTICALS, INC. | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137349-A1 | ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS | OXA1L, NISCH, ODC1 | TSHR 3650/4885CYP2C19 62/4885POLB 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.